---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-241846"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-05-27T20:01:51+00:00"
generated_at: "2026-05-27T20:06:25.973899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials

## Summary
- Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.
- Investors include BVF Partners, RA Capital, OrbiMed, Atlas Venture; led by BVF.
- Closing expected May 28, 2026; net proceeds to advance bempikibart clinical trials and for working capital.
- Registration rights agreement filed to register resale of shares and warrant shares.

## SEC filing metadata
- accession: 0001193125-26-241846
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-05-27T20:01:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526241846/0001193125-26-241846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526241846/d228038d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-241846
- JSON: https://secwatch.observer/filing/0001193125-26-241846.json
- Plain text: https://secwatch.observer/filing/0001193125-26-241846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.